|Healthcare Review: Herbalife Ltd , Rosetta Genomics, NuVasive, Arena Pharmaceuticals, Dynavax Technologies Corporation|
|By Staff and Wire Reports|
|Wednesday, 09 January 2013 14:04|
Stocks, having rallied after a last-minute resolution stopped the U.S. going from over the "fiscal cliff," are facing their first challenge of the year as companies start to report their earnings for the fourth quarter of 2012. Throughout last year, analysts had cut their outlook for earnings growth in the period and now expect them to rise by 3.21 percent, according to data from S&P Capital IQ.
Following are the notable movers at mid day on Wednesday:
Herbalife Ltd. (NYSE:HLF) shares climbed 1.28% to $38.81. One of Herbalife’s biggest independent distributors has left the company to sell energy drinks and he’s exhorting his 16,000 distributors to join him. Anthony Powell will distribute Verve energy-drink products for Scottsdale, Arizona-based Vemma Nutrition Co., he said in a webcast to his distributors Jan. 6. Spokesmen for Vemma and Herbalife confirmed the move. Powell didn’t respond to messages seeking comment.
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares jumped 17.91% to $5.43 after the company announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled "Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors."
NuVasive, Inc. (NASDAQ:NUVA) stock climbed 10.41% to $17.40 after the company announced preliminary unaudited revenue results for the full year ended December 31, 2012. NuVasive anticipates full year 2012 revenue of approximately $619 million. The unaudited results compare to previously issued guidance of $601 million to $606 million in revenue for the full year 2012. NuVasive expects 2013 revenue to approximate $655 million.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock decreased 4.16% to $9.69. The company announced that the company is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013, at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview.
Dynavax Technologies Corporation (NASDAQ:DVAX) shares climbed 7.52% to $3.29. J.P. Morgan & Co. initiated coverage on Dynavax with a Neutral rating on Jan. 2. J.P. Morgan initiated coverage of Dynavax (DVAX) with a Neutral rating. Dynavax is a clinical stage biotechnology company with a focus on infectious and inflammatory diseases. The company has a number of interesting early-stage candidates in the pipeline, but the key potential value driver is the lead asset HEPLISAV, which has been submitted to the FDA for the active immunization against all subtypes of hepatitis B virus infection in adults 18-70 years of age.